メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
第４・内科
病院局
岡崎医療センター
概要
フィンガープリント
ネットワーク
プロファイル
(1)
研究成果
(44)
フィンガープリント
第４・内科が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Chemotherapy
69%
Large Cell Lymphoma
40%
Nonhodgkin Lymphoma
40%
Etoposide
40%
Vincristine
40%
Cyclophosphamide
40%
Prednisolone
40%
Doxorubicin
40%
Remission
38%
Clinical Trial
27%
Progression Free Survival
24%
B Cell Lymphoma
22%
Survival Rate
21%
Fluorodeoxyglucose F 18
20%
Nucleoside Diphosphate Kinase A
20%
Acute Myeloid Leukemia
20%
Disease
20%
Ifosfamide
20%
Carboplatin
20%
Combination Therapy
20%
Dexamethasone
20%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Methotrexate
20%
Acute Leukemia
20%
Intrathecal
20%
Interleukin 1
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Human Herpesvirus 8
20%
Angiofollicular Lymph Node Hyperplasia
20%
Circulating Tumor DNA
20%
Tumor Lysis Syndrome
20%
Herpes Zoster
20%
Granulocyte Colony Stimulating Factor
20%
Bleomycin
20%
Pharmacokinetics
20%
Adverse Event
15%
Anasarca
10%
Reticulin
10%
Disease Free Survival
10%
Infection
6%
Overall Survival
6%
Malignant Neoplasm
6%
Cytotoxicity
5%
Immunoglobulin
5%
De Novo Acute Myeloid Leukemia
5%
Lactate Dehydrogenase
5%
Mercaptopurine
5%
Vindesine
5%
Dasatinib
5%
Thrombocytopenia
5%
Stomatitis
5%
T Cell Leukemia
5%
Liver Dysfunction
5%
Granulocytopenia
5%
Keyphrases
Intravascular Large B-cell Lymphoma (IVLBCL)
40%
Retrospective Analysis
40%
Chemotherapy
24%
Adult Acute Lymphoblastic Leukemia
20%
Aggressive non-Hodgkin Lymphoma
20%
Induction Failure
20%
Japan Clinical Oncology Group
20%
Japan
20%
B-cell Markers
20%
Laboratory Medicine
20%
Rituximab-containing Chemotherapy
20%
Extranodal Marginal Zone B-cell Lymphoma of mucosa-associated Lymphoid Tissue
20%
Serum IgG Level
20%
Relapsed Lymphoma
20%
CBDCA
20%
R-CHOP Therapy
20%
Combination of Therapies
20%
System Restoration
20%
Dose-adjusted EPOCH-R
20%
Epstein-Barr Virus-positive mucocutaneous Ulcer
20%
Flow Cytometric
20%
Cerebrospinal Fluid
20%
Circulating Tumor DNA (ctDNA)
20%
Central Nervous System Relapse
20%
Hematology
20%
Tumor Lysis Syndrome
20%
Spinal Cord
20%
Upper Part
20%
Lymphoma
20%
Antibody-mediated Immunity
20%
IgG Levels
20%
Aggressive B-cell Lymphoma
20%
Central Nervous System Involvement
20%
Central Nervous System Recurrence
15%
Intrathecal Methotrexate
15%
Early Molecular Response
13%
High-risk Cases
13%
Calvert Formula
11%
Rituximab
11%
Ann Arbor Staging
10%
Immunosenescence
10%
Post-chemotherapy
10%
Progression-free Survival
8%
Working Diagnosis
8%
Curative Effect
8%
Overall Survival
6%
MALT1 Gene
6%
Method Parameters
6%
Lymphocyte Count
6%
R-CHOP-14
6%
R-CHOP-21
6%
CD20+
6%
Second-generation Tyrosine Kinase Inhibitors
6%
Dasatinib
6%
BCR-ABL1
6%
Vascular Adverse Events
6%
Hazard Ratio
6%
Initial Diagnosis
6%
Genomic Imbalances
6%
CD35
5%
Post-remission Chemotherapy
5%
Vindesine
5%
6-mercaptopurine (6-MP)
5%
Response Group
5%
Adjusted Dose
5%
Large B-cell
5%
Epstein-Barr Virus mucocutaneous Ulcer
5%
Immunoglobulin Heavy Chain
5%
Gingiva
5%
Reed-Sternberg Cells
5%
Mucocutaneous Ulcer
5%
Bolus Administration
5%
Previously Treated Patients
5%
Intravenous Bolus
5%
PR-4
5%
Medicine and Dentistry
Rituximab
68%
Large-Cell Lymphoma
60%
B-Cell Lymphoma
43%
Methotrexate
40%
Drug Megadose
40%
Arm
40%
Diffuse Large B-Cell Lymphoma
40%
Human Herpesvirus 8
40%
Progression Free Survival
25%
Doxorubicin
24%
Vincristine
24%
Cyclophosphamide
24%
Hematology
24%
Cyclin D1
23%
Mantle Cell Lymphoma
23%
Central Nervous System
22%
Prednisolone
22%
Nucleoside Diphosphate Kinase A
20%
Laboratory Medicine
20%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Myeloid Leukemia
20%
Intrathecal Drug Administration
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Magnetic Resonance Imaging
20%
Cerebrospinal Fluid
20%
Effusion
20%
Circulating Tumor DNA
20%
Disseminated Herpes Zoster
20%
Pharmacokinetics
20%
Organomegaly
13%
Infusion
13%
Recurrent Disease
10%
CD20
8%
Aggressive Lymphoma
8%
Adverse Event
8%
Clinical Trial
8%
Neutropenia
6%
Febrile Neutropenia
6%
Immunoglobulin
6%
B Cell
6%
Disease
5%
Rare Disease
5%
Malignant Neoplasm
5%
Mitoxantrone
5%
Mercaptopurine
5%
Vindesine
5%
Dasatinib
5%
Nilotinib
5%
Granulocytopenia
5%